Accessibility Menu
Alterity Therapeutics logo

Alterity Therapeutics(ASX) ATH

Market CapA$116.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-99%
5 Year-66%
1 Year-16%
1 Month-5%
A$0.55
+1.87%
+0.01Today
Alterity Therapeutics last closing stock price
MetricPriceDate
Last closeAUD 0.552026-08-14
Alterity Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.83%AUD 0.522026-08-07
1 month-5.22%AUD 0.582026-07-15
3 month+9%AUD 0.502026-05-15
Year to date+36.25%AUD 0.402025-12-31
1 year-16.15%AUD 0.652025-08-14
3 year+55.71%AUD 0.352023-08-15
5 year-65.94%AUD 1.602021-08-13
Since inception-98.95%AUD 51.002000-03-28

Alterity Therapeutics Financials at a Glance

Market Cap

A$116.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$7.56M

Net Income (TTM)

-A$34.38M

EPS (TTM)

-A$0.07

P/E Ratio

-7.18

Dividend

A$0.00

Beta (Volatility)

0.31 (Low)

Price

A$0.55

Volume

359,630

Open

A$0.54

Previous Close

A$0.55

Daily Range

A$0.51 - A$0.55

52-Week Range

A$0.35 - A$0.79

Estimated Earnings Date

Aug 28, 2026

ATH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alterity Therapeutics

Alterity Therapeutics Limited is a biotechnology company based in Melbourne, Australia, focused on developing innovative treatments for neurological conditions, including Alzheimer's, Huntington's, and Parkinson's diseases. The company is advancing its primary drug candidate, ATH434, which has successfully completed Phase I clinical trials for Parkinson's disease, and is also progressing PBT2, an investigational compound for Alzheimer's disease.

Products and Services
  • ATH434: A drug candidate for Parkinson's disease
  • PBT2: Investigational compound for Alzheimer's disease
  • Research and development in neurological conditions
Growth Outlook
  • Strong pipeline with two promising drug candidates in clinical trials
  • Focus on addressing significant unmet medical needs in neurology
  • Potential for partnerships to enhance development and commercialization
Financial Highlights
  • Recent quarterly revenue of AUD 3.83 million, showing growth potential
  • Cash and cash equivalents of AUD 49.2 million, providing operational runway
  • Current ratio of 21.98, indicating strong liquidity position
Alterity Therapeutics Limited is positioned in a critical sector of healthcare, targeting neurological diseases that affect millions globally. The company's commitment to research and development is evident in its advanced drug candidates, which have the potential to significantly impact patient care. The financial position, highlighted by substantial cash reserves and a strong current ratio, supports ongoing operations and future growth initiatives. Investors may find the company's focus on unmet medical needs and potential for strategic partnerships appealing as it navigates the complexities of drug development in the biotechnology landscape.
AI Generated • Jul 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

9

CEO

David A. Stamler, MD

Website

www.alteritytherapeutics.com

Headquarters

Melbourne, VIC 3000, AU

ATH Financials

Key Financial Metrics (TTM)

Gross Margin

96.82%

Operating Margin

-525.58%

Net Income Margin

-380.65%

Return on Equity

-30.19%

Return on Capital

-34.25%

Return on Assets

-25.63%

Earnings Yield

-13.93%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$116.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

217.98M

Volume

359.63K

Avg. Volume

205.27K

Financials (TTM)

Gross Profit

A$7.30M

Operating Income

-A$42.73M

EBITDA

-A$42.25M

Operating Cash Flow

-A$29.45M

Capital Expenditure

A$10.62M

Free Cash Flow

-A$18.83M

Cash & ST Invst.

A$49.20M

Total Debt

A$163.91K

Alterity Therapeutics Performance Analysis

Alterity Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 0N/A
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
Alterity Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3011.5%
Q22024-12-31-24.2%
Q42025-06-30138.7%
Q22025-12-31-100.0%
Alterity Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.27N/A
20232023-06-30AUD -0.286.6%
20242024-06-30AUD -0.26-7.9%
20252025-06-30AUD -0.10-63.7%
Alterity Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3023.1%
Q22024-12-3130.0%
Q42025-06-3050.0%
Q22025-12-31-34.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$57.89K

-103.2%

Gross Margin

0.00%

N/A

Market Cap

A$116.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$12.96M

N/A

Employees

9

N/A

Net Income

-A$9.62M

-47.8%

EBITDA

-A$13.00M

-56.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$49.20M

+299.3%

Total Debt

A$163.91K

-35.9%

Accounts Receivable

A$6.84M

+17.9%

Inventory

A$0.00

N/A

Long Term Debt

A$130.92K

+71.1%

Short Term Debt

A$32.99K

-81.6%

Return on Assets

-25.63%

N/A

Return on Invested Capital

-37.08%

N/A

Free Cash Flow

A$0.00

+100.0%

Operating Cash Flow

-A$10.62M

-136.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RCE.AXRecce Pharmaceuticals Ltd
A$0.37-1.33%
ILA.AXIsland Pharmaceuticals Limited
A$0.44-4.35%
ALA.AXArovella Therapeutics Limited
A$0.06+3.33%
ACW.AXActinogen Medical Limited
A$0.05-2.17%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About ATH

What is the current price of Alterity Therapeutics?

Alterity Therapeutics is trading at A$0.55 per share.

What is the 52-week range for Alterity Therapeutics?

Over the past 52 weeks, Alterity Therapeutics has traded between A$0.35 and A$0.79.

How much debt does Alterity Therapeutics have?

As of the most recent reporting period, Alterity Therapeutics reported total debt of A$155.46K.

How much cash does Alterity Therapeutics have on hand?

Alterity Therapeutics reported A$33.16M in cash and cash equivalents in its most recent financial results.

What is Alterity Therapeutics’s dividend yield?

Alterity Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services